These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34180282)

  • 1. Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection.
    Med Lett Drugs Ther; 2021 May; 63(1625):81-83. PubMed ID: 34180282
    [No Abstract]   [Full Text] [Related]  

  • 2. Juluca - a two-drug complete regimen for HIV.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):e202-e204. PubMed ID: 30653480
    [No Abstract]   [Full Text] [Related]  

  • 3. Odefsey--another NNRTI combination for HIV.
    Med Lett Drugs Ther; 2016 May; 58(1494):60-1. PubMed ID: 27148923
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
    Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Extended-Release Injectable Drug Therapy for HIV.
    Aschenbrenner DS
    Am J Nurs; 2021 May; 121(5):24-25. PubMed ID: 33872258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
    Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C
    Clin Pharmacokinet; 2021 Jul; 60(7):835-853. PubMed ID: 33830459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
    Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
    PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early virological failure with cabotegravir/rilpivirine.
    Bailón L; Sábato S; Coll J; Santos JR; Miranda C; Puig T; D Avolio A; Paredes R; Moltó J; Negredo E
    J Antimicrob Chemother; 2024 May; 79(5):1193-1194. PubMed ID: 38385520
    [No Abstract]   [Full Text] [Related]  

  • 10. Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
    Troya J; Ryan P; Montejano R; Cabello A; Cuevas G; Matarranz M; Cañamares I; Solís J; Walther LÁ
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):423-426. PubMed ID: 30443683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).
    Penrose KJ; Parikh UM; Hamanishi KA; Else L; Back D; Boffito M; Jackson A; Mellors JW
    J Infect Dis; 2016 Mar; 213(6):1013-7. PubMed ID: 26563240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of rilpivirine drug-induced liver injury.
    Lee MJ; Berry P; D'Errico F; Miquel R; Kulasegaram R
    Sex Transm Infect; 2020 Dec; 96(8):618-619. PubMed ID: 31974214
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations.
    Cilento ME; Ong YT; Tedbury PR; Sarafianos SG
    Viruses; 2022 May; 14(6):. PubMed ID: 35746673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symfi, Symfi Lo, and Cimduo for HIV.
    Med Lett Drugs Ther; 2019 Jan; 61(1563):e8-e10. PubMed ID: 30681663
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
    Hester EK; Astle K
    Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
    [No Abstract]   [Full Text] [Related]  

  • 18. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
    Blackwell CW; López Castillo H
    J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling.
    Rajoli RKR; Curley P; Chiong J; Back D; Flexner C; Owen A; Siccardi M
    J Infect Dis; 2019 May; 219(11):1735-1742. PubMed ID: 30566691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
    Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.